The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

Haddad, Fatma; Dokmak, Ghadeer

doi:10.3390/life12050682

Cited by 20 publications

(24 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the indication muscle spasm, these results were comparable. A recent review supported Sativex’s ® (an oral spray of balanced Δ-9-THC and CBD) effectiveness on multiple sclerosis pain and spasticity, with improvements in sleep and QoL [ 38 ]. Another prospective study found 70.5% of patients reported a ≥20% improvement in symptoms after one month [ 39 ], which agrees with our results.…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

Morris

Chye

Liu

et al. 2023

JCM

View full text Add to dashboard Cite

Research describing patients using medicinal cannabis and its effectiveness is lacking. We aimed to describe adults with non-cancer diagnoses who are prescribed medicinal cannabis via a retrospective medical record review and assess its effectiveness and safety. From 157 Australian records, most were female (63.7%; mean age 63.0 years). Most patients had neurological (58.0%) or musculoskeletal (24.8%) conditions. Medicinal cannabis was perceived beneficial by 53.5% of patients. Mixed-effects modelling and post hoc multiple comparisons analysis showed significant changes overtime for pain, bowel problems, fatigue, difficulty sleeping, mood, quality of life (all p < 0.0001), breathing problems (p = 0.0035), and appetite (p = 0.0465) Symptom Assessment Scale scores. For the conditions, neuropathic pain/peripheral neuropathy had the highest rate of perceived benefit (66.6%), followed by Parkinson’s disease (60.9%), multiple sclerosis (60.0%), migraine (43.8%), chronic pain syndrome (42.1%), and spondylosis (40.0%). For the indications, medicinal cannabis had the greatest perceived effect on sleep (80.0%), followed by pain (51.5%), and muscle spasm (50%). Oral oil preparations of balanced delta-9-tetrahydrocannabinol/cannabidiol (average post-titration dose of 16.9 mg and 34.8 mg per day, respectively) were mainly prescribed. Somnolence was the most frequently reported side effect (21%). This study supports medicinal cannabis’ potential to safely treat non-cancer chronic conditions and indications.

show abstract

Section: Discussionmentioning

confidence: 99%

A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

Morris

Chye

Liu

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…Pain experienced by MS patients can be divided into multiple categories, such as continuous central neuropathic pain, intermittent central neuropathic pain, musculoskeletal pain, and mixed neuropathic and non-neuropathic pain. 167 Treatment should ideally be targeted towards the specific modality experienced by the patients. Indirect or secondary causes of pain such as spasticity, alteration of gait mechanics, or fatigue should be managed separately (and are addressed in other sections of the paper).…”

Section: Painmentioning

confidence: 99%

Managing the Symptoms of Multiple Sclerosis

Sneha¹,

Lauren²,

Langston³

2023

MRAJ

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that is characterized by recurrent bouts of acute neuroinflammation and chronic neurodegeneration. Treatments for MS are aimed at prevention of disability in the future or restoring function in the present. Prevention treatments disrupt the underlying disease pathology, whereas restorative treatments address not only the disease’s primary effects on the central nervous system, but also secondary effects on other parts of the body and tertiary effects on each patient’s psychosocial functioning. MS symptoms can have primary, secondary, and tertiary components, which can interlock and reinforce each other. Restorative treatment should tease apart these components and address them separately. In this article on symptom management, we focus on treatments that aim to maximize each component of function.

show abstract

“…Many reports demonstrated the beneficial effects of cannabinoids in multiple sclerosis based on their immunosuppressive, neuroprotective, remyelinating and analgesic effects [ 261 , 262 , 263 ]. For example, in Theiler’s virus infection of the CNS, which induces an immune-mediated demyelinating disease resembling multiple sclerosis, synthetic CBR agonists WIN 55,212–2 (nonselective CB1/CB2 agonist), ACEA (selectivity over CB1R), and JWH-015 (selectivity over CB2R) improved motor functions, reduced microglial activation and number of CD4+ infiltrating T-cells in the spinal cord, and promoted remyelination in infected animals, clearly suggesting the therapeutic potential of targeting ECS in multiple sclerosis [ 264 ].…”

Section: Cb2r In Multiple Sclerosismentioning

confidence: 99%

Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential

et al. 2022

View full text Add to dashboard Cite

Some of the most prevalent neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease, are proteinopathies characterized by the accumulation of specific protein aggregates in the brain. Such misfolded protein aggregates can trigger modulation of the innate and adaptive immune systems and subsequently lead to chronic neuroinflammation that drives the onset and progression of neurodegenerative diseases. Since there is still no effective disease-modifying treatment, new therapeutic targets for neurodegenerative proteinopathies have been sought. The endocannabinoid system, and in particular the cannabinoid CB2 receptors, have been extensively studied, due to their important role in neuroinflammation, especially in microglial cells. Several studies have shown promising effects of CB2 receptor activation on reducing protein aggregation-based pathology as well as on attenuating inflammation and several dementia-related symptoms. In this review, we discuss the available data on the role of CB2 receptors in neuroinflammation and the potential benefits and limitations of specific agonists of these receptors in the therapy of neurodegenerative proteinopathies.

show abstract

The Efficacy of Cannabis on Multiple Sclerosis-Related Symptoms

Cited by 20 publications

References 119 publications

A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

A Retrospective Medical Record Review of Adults with Non-Cancer Diagnoses Prescribed Medicinal Cannabis

Managing the Symptoms of Multiple Sclerosis

Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential

Contact Info

Product

Resources

About